TABLE 3.
Previous Studies of Hormonal Treatment and apoA-I Kinetics
| Reference | Subjects | Treatment | Fraction | ApoA-I* | ApoA-I FCR† | ApoA-I PR‡ |
|---|---|---|---|---|---|---|
| Schaefer et al41 | Pre-mp, N=4 | Ethinyl estradiol | HDL | +24%§ | −3% | +17%§ |
| Hazzard et al44 | Post-mp, N=1 | Ethinyl estradiol | HDL | +29% | −42% | −37% |
| Quintao et al9 | Post-mp, N=7 | 17β-estradiol | HDL | +16%§ | −45%§ | |
| Walsh et al10 | Post-mp, N=8 | 17β-estradiol | HDL2 | +37%§ | +3% | +36%§ |
| HDL3 | +12%§ | +10% | +19%§ | |||
| Walsh et al10 | Post-mp, N=8 | 17β-estradiol, transdermal | HDL2 | +3% | +8% | +7% |
| HDL3 | −7% | +14% | +4% | |||
| Brinton11 | Post-mp, N=6 | Ethinyl estradiol | LpAI | +66%§ | +7% | +76%§ |
| LpAIAII | +14% | +5% | +22% | |||
| Haffner et al46 | Post-mp, N=4 | Stanozolol | HDL | −55%§ | +62% | −35% |
| Current study | Post-mp, N=7 | CEE (vs placebo) | HDL | +20%§ | +20% | +47%§ |
| N=8 | MPA+CEE (vs CEE) | HDL | −8%§ | −5% | −13%§ | |
| N=7 | MPA+CEE (vs placebo) | HDL | +9% | +13% | +26% |
Post-mp indicates postmenopause; Pre-mp, premenopause.
*
Percent change in plasma apo A-I concentration from control phase (placebo or baseline), unless otherwise specified.
†
Percent change in apoA-I FCR from control phase (placebo or baseline), unless otherwise specified.
‡
Percent change in apoA-I PR from control phase (placebo or baseline), unless otherwise specified.
§
Statistically significant, P<0.05.